Tarsa Completes Phase III For Oral Calcitonin In Osteoporosis, Plans 2011 NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Initially, biotech will pursue a treatment indication but also has its recombinant oral formulation in Phase II for osteoporosis prevention.